Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Apr 14;11(8):2197.
doi: 10.3390/jcm11082197.

Botulinum Toxin A Treatment in HIV Infected Patients-A Long-Term Observational Study

Stefan Evers  1   2 , Alexandra Buchheister  3 , Doris Reichelt  4 , Ingo W Husstedt  3 , Achim Frese  5
Affiliations
Case Reports

Botulinum Toxin A Treatment in HIV Infected Patients-A Long-Term Observational Study

Stefan Evers et al. J Clin Med. .

Abstract

Objective: It is unknown whether interactions between HIV infection and the safety of botulinum toxin A (BTX) exist.

Methods: We studied eight patients with HIV infection who were treated with BTX every three months for up to nine years. All patients were on antiretroviral treatment. The efficacy and safety of BTX were evaluated.

Results: Indications for BTX treatment (including off-label use), dosage of BTX, and frequency of application did not differ as compared to non-HIV infected patients. BTX treatment was effective in all HIV infected patients during a long-term observation period without loss of efficacy and without clinically relevant side effects. Only one of the eight patients showed mild side effects due to BTX, and no clinical signs of antibody development were noted. We also observed no signs of interaction with antiretroviral treatment. CD4+ cell count and viral load remained stable during the observation period.

Conclusions: We conclude that BTX treatment is safe and effective in the treatment of HIV infected patients who suffer also from a condition which can be treated by BTX. It is a therapeutic option in addition to oral medication for HIV infected patients.

Keywords: HIV infection; botulinum toxin; dystonia; spasticity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Keam S.J., Muir V.J., Deeks E.D. Botulinum toxin A (Dysport®): In dystonias and focal spasticity. Drugs. 2011;71:1043–1058. doi: 10.2165/11206340-000000000-00000. - DOI - PubMed
    1. Frampton J.E. Onabotulinumtoxin A (BOTOX®): A review of its use in the prophylaxis of headaches in adults with chronic migraine. Drugs. 2012;72:825–845. doi: 10.2165/11208880-000000000-00000. - DOI - PubMed
    1. Tse W., Cersosimo M.G., Gracies J.M., Morgello S., Olanow C.W., Koller W. Movement. disorders and AIDS: A review. Parkinsonism Relat. Disord. 2004;10:323–334. doi: 10.1016/j.parkreldis.2004.03.001. - DOI - PubMed
    1. Cardoso F. HIV-related movement disorders: Epidemiology, pathogenesis and management. CNS Drugs. 2002;16:663–668. doi: 10.2165/00023210-200216100-00002. - DOI - PubMed
    1. Scheller C., Arendt G., Nolting T., Antke C., Sopper S., Maschke M., Obermann M., Angerer A., Husstedt I.W., Meisner F., et al. Increased dopaminergic neurotransmission in therapy-naïve asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses. J. Neurol. Transm. 2010;117:699–705. doi: 10.1007/s00702-010-0415-6. - DOI - PubMed

Publication types